Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides

Thrombosis Research

Volumn 119, Issue 5, 2007, Pages 653-661

  Ma, Qing ^a   Tobu, Mahmut ^a   Schultz, Christopher ^a   Jeske, Walter ^a   Hoppensteadt, Debra ^a   Walenga, Jeanine ^a   Cornelli, Umberto ^a   Lee, John ^a   Linhardt, Robert ^b   Hanin, Israel ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b Research Rensselaer Polytechnic Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; GAMMAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OLIGOSACCHARIDE; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FUNCTION TEST; IMMUNOLOGICAL PROCEDURES; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIMATE; PRIORITY JOURNAL;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LIPOPROTEINS; MACACA MULATTA; MALE; MOLECULAR WEIGHT; OLIGOSACCHARIDES; TIME FACTORS;

EID: 33847240062     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.05.007     Document Type: Article

References (28)

1. Kaiser B., Hoppensteadt D.A., and Fareed J. Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opin Investig Drugs 10 (2001) 1925-1935
2. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 22 (2002) 539-548
3. Broze Jr. G.J. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 29 (1992) 159-169
4. Lindahl A.K., Jacobsen P.B., Sandset P.M., and Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis 2 (1991) 713-721
5. Sandset P.M., and Abildgaard U. Extrinsic pathway inhibitor-the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 21 (1991) 219-239
6. Sandset P.M., Abildgaard U., and Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50 (1988) 803
7. Lindahl A.K., Abildgaard U., Larsen M.L., Staalesen R., Hammer A.K., Sandset P.M., et al. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res Suppl. 14 (1991) 39
8. Hansen J.B., Sandset P.M., Huseby K.R., Huseby N.E., Bendz B., Ostergaard P., et al. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol 101 (1998) 638
9. Hansen J.B., Sandset P.M., Huseby K.R., Huseby N.E., and Nordoy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 76 (1996) 703
10. Bendz B., Andersen T.O., and Sandset P.M. Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. Blood Coagul Fibrinolysis 11 (2000) 343
11. Bendz B., Hansen J.B., Andersen T.O., Ostergaard P., and Sandset P.M. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. Br J Haematol 107 (1999) 756
12. Ma Q., Dudas B., Daud A., Iqbal O., Hoppensteadt D., Jeske W., et al. Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3. Thromb Res 105 (2002) 303
13. Hirsh J., Anand S.S., Halperin J.L., and Fuster V. AHA Scientific Statement: guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vasc Biol 21 (2001) E9
14. Novotny W.F., Palmier M., Wun T.C., Broze Jr. G.J., and Miletich J.P. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 78 (1991) 394-400
15. Girard T.J., Warren L.A., Novotny W.F., Likert K.M., Brown S.G., Miletich J.P., et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338 (1989) 518-520
16. Valentin S., Larnkjer A., Ostergaard P., Nielsen J.I., and Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 75 (1994) 173-183
17. Ostergaard P., Nordfang O., Petersen L.C., Valentin S., and Kristensen H. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations. Haemostasis 23 Suppl. 1 (1993) 107-111
18. Nordfang O., Valentin S., Beck T.C., and Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 66 (1991) 464-467
19. Bendz B., Andersen T.O., and Sandset P.M. A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1. Thromb Res 97 (2000) 463-472
20. Ostergaard P.B., Beck T.C., Orsted H., Svendsen A., Nordfang O., Sandset P.M., et al. An enzyme linked immunosorption assay for tissue factor pathway inhibitor. Thromb Res 87 (1997) 447-459
21. Hansen J.B., Naalsund T., Sandset P.M., and Svensson B. Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin. Thromb Res 100 (2000) 413-417
22. Jeske W., Hoppensteadt D., Callas D., Koza M.J., and Fareed J. Pharmacological profiling of recombinant tissue factor pathway inhibitor. Semin Thromb Hemost 22 (1996) 213-219
23. Ma Q., Schultz C., Neville B., Jeske W., Hoppensteadt D., Cornelli U., et al. Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates. Thromb Res 112 (2003) 249-255
24. Hansen J.B., and Sandset P.M. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. Thromb Res 91 (1998) 177
25. Kemme M.J., Burggraaf J., Schoemaker R.C., Kluft C., and Cohen A.F. Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. Br J Clin Pharmacol 54 (2002) 627-634
26. Esmon C.T. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 196 (2002) 561-564
27. Mine S., Yamazaki T., Miyata T., Hara S., and Kato H. Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Biochemistry 41 (2002) 78-85
28. Xu X., Takano R., Nagai Y., Yanagida T., Kamei K., Kato H., et al. Effect of heparin chain length on the interaction with tissue factor pathway inhibitor (TFPI). Int J Biol Macromol 30 (2002) 151-160